Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: AGA BETA BS Switch in Fabry Disease
NCT05843916Phase 3Completed
- Sponsor
- Biosidus
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, open-label trial in Fabry disease (FD), sponsored by Biosidus. Primary endpoint: Globotriaosylsphingosine at 26 weeks. Started Dec 2022; status: completed.
02
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05843916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843916.